十四天替戈普拉赞-阿莫西林双重疗法作为幽门螺旋杆菌感染的一线治疗方法(SHARE2301):一项多中心、非劣效性、随机临床试验。

IF 4.3 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Helicobacter Pub Date : 2024-06-09 DOI:10.1111/hel.13098
Qingzhou Kong, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, Yuting Guo, Yanan Yu, Xiuli Zuo, Yanqing Li, Yueyue Li
{"title":"十四天替戈普拉赞-阿莫西林双重疗法作为幽门螺旋杆菌感染的一线治疗方法(SHARE2301):一项多中心、非劣效性、随机临床试验。","authors":"Qingzhou Kong,&nbsp;Iqtida Ahmed Mirza,&nbsp;Xiaoqian Zhang,&nbsp;Xiaohui Song,&nbsp;Xiaowei Li,&nbsp;Qiumei Zhang,&nbsp;Lidong Xu,&nbsp;Yuting Guo,&nbsp;Yanan Yu,&nbsp;Xiuli Zuo,&nbsp;Yanqing Li,&nbsp;Yueyue Li","doi":"10.1111/hel.13098","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Potassium-competitive acid blockers have demonstrated enormous potential in the eradication treatment of <i>Helicobacter pylori</i> infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>The multicenter, noninferiority, randomized-controlled trial was conducted from May 2023 to March 2024. Treatment-naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by <sup>13</sup>C-urea breath test, including per-protocol (PP) analysis and intention-to-treat (ITT) analysis. Secondary outcomes were adverse events and compliance.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (<i>p</i> = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (<i>p</i> = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (<i>p</i> = 0.0023) and ITT analyses (<i>p</i> = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (<i>p</i> &lt; 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first-line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov ID: NCT05870683.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fourteen-Day Tegoprazan–Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial\",\"authors\":\"Qingzhou Kong,&nbsp;Iqtida Ahmed Mirza,&nbsp;Xiaoqian Zhang,&nbsp;Xiaohui Song,&nbsp;Xiaowei Li,&nbsp;Qiumei Zhang,&nbsp;Lidong Xu,&nbsp;Yuting Guo,&nbsp;Yanan Yu,&nbsp;Xiuli Zuo,&nbsp;Yanqing Li,&nbsp;Yueyue Li\",\"doi\":\"10.1111/hel.13098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Potassium-competitive acid blockers have demonstrated enormous potential in the eradication treatment of <i>Helicobacter pylori</i> infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>The multicenter, noninferiority, randomized-controlled trial was conducted from May 2023 to March 2024. Treatment-naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by <sup>13</sup>C-urea breath test, including per-protocol (PP) analysis and intention-to-treat (ITT) analysis. Secondary outcomes were adverse events and compliance.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (<i>p</i> = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (<i>p</i> = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (<i>p</i> = 0.0023) and ITT analyses (<i>p</i> = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (<i>p</i> &lt; 0.001).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first-line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov ID: NCT05870683.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13223,\"journal\":{\"name\":\"Helicobacter\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Helicobacter\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hel.13098\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.13098","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:钾竞争性酸阻滞剂在根除幽门螺旋杆菌感染的治疗中表现出巨大的潜力,替戈普拉赞就是其中的代表之一。有关替戈普拉赞在双重疗法中的安全性和有效性的现有数据十分有限:多中心、非劣效、随机对照试验于 2023 年 5 月至 2024 年 3 月进行。未经治疗的受试者被随机分配(1:1)进入替戈普拉嗪-阿莫西林(TA)组(替戈普拉嗪 50 毫克,每天两次,阿莫西林 750 毫克,每天四次)或埃索美拉唑-阿莫西林(EA)组(埃索美拉唑 20 毫克,阿莫西林 750 毫克,每天四次),疗程均为 14 天。主要结果是通过13C-尿素呼气试验确定的根除率,包括每方案(PP)分析和意向治疗(ITT)分析。次要结果为不良事件和依从性:结果:共有 368 人参与了随机分组。根据 ITT 分析(p = 0.77),EA 组和 TA 组的根除率分别为 84.2% 和 85.8%;根据 PP 分析(p = 1.00),EA 组和 TA 组的根除率分别为 88.5% 和 88.2%。在 PP 分析(p = 0.0023)和 ITT 分析(p = 0.0009)中,TA 组的根除率均不低于 EA 组。两组的不良反应发生率和依从性无明显统计学差异。多变量逻辑回归分析显示,依从性差会增加根除失败的风险(p 结论:依从性差会增加根除失败的风险:含有替戈普拉赞的双重疗法安全有效,可作为临床一线治疗选择,但需要进一步优化,包括抗菌药敏感性检测以及剂量和频率的调整:试验注册:ClinicalTrials.gov ID:试验注册:ClinicalTrials.gov ID:NCT05870683。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Fourteen-Day Tegoprazan–Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial

Background

Potassium-competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.

Materials and Methods

The multicenter, noninferiority, randomized-controlled trial was conducted from May 2023 to March 2024. Treatment-naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by 13C-urea breath test, including per-protocol (PP) analysis and intention-to-treat (ITT) analysis. Secondary outcomes were adverse events and compliance.

Results

A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (p = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (p = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (p = 0.0023) and ITT analyses (p = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (p < 0.001).

Conclusions

Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first-line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.

Trial Registration

ClinicalTrials.gov ID: NCT05870683.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Helicobacter
Helicobacter 医学-微生物学
CiteScore
8.40
自引率
9.10%
发文量
76
审稿时长
2 months
期刊介绍: Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.
期刊最新文献
Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam Map-Like Redness Development After Eradication Therapy for Helicobacter pylori Infection: Prospective Multicenter Observational Study Issue Information Correction to Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008–2023): A Systematic Review Influence of oipA Phase Variation on Virulence Phenotypes Related to Type IV Secretion System in Helicobacter pylori
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1